Related Experiment Video
Updated: May 2, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Fungemia by Wickerhamomyces anomalus-A Narrative Review
Petros Ioannou1, Stella Baliou1, Diamantis P Kofteridis1
1School of Medicine, University of Crete, 71003 Heraklion, Greece.
Abstract:
Wickerhamomyces anomalus has been previously classified as Hansenula anomala, Pichia anomala, and Candida pelliculosa and was recently reclassified in the genus Wickerhamomyces after phylogenetic analysis of its genetic sequence. An increasing number of reports of human infections by W. anomalus have emerged, suggesting that this microorganism is an emerging pathogen. The present review aimed to provide data on the epidemiology, antifungal resistance, clinical characteristics, treatment, and outcomes of fungemia by W. anomalus by extracting all the available information from published original reports in the literature. PubMed/Medline, Cochrane Library, and Scopus databases were searched for eligible articles reporting data on patients with this disease. In total, 36 studies involving 170 patients were included. The age of patients with fungemia by W. anomalus ranged from 0 to 89 years; the mean age was 22.8 years, the median age was 2.2 years, with more than 37 patients being less than one month old, and 54% (88 out of 163 patients) were male. Regarding patients' history, 70.4% had a central venous catheter use (CVC), 28.7% were on total parenteral nutrition (TPN), 97% of neonates were hospitalized in the neonatal ICU (NICU), and 39.4% of the rest of the patients were hospitalized in the intensive care unit (ICU). Previous antimicrobial use was noted in 65.9% of patients. The most common identification method was the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in 34.1%, VITEK and VITEK 2 in 20.6%, and ID32 C in 15.3%. W. anomalus had minimal antifungal resistance to fluconazole, echinocandins, and amphotericin B, the most commonly used antifungals for treatment. Fever and sepsis were the most common clinical presentation noted in 95.8% and 86%, respectively. Overall mortality was 20% and was slightly higher in patients older than one year. Due to the rarity of this disease, future multicenter studies should be performed to adequately characterize patients' characteristics, treatment, and outcomes, which will increase our understanding and allow drawing safer conclusions regarding optimal management.
Insights
Wickerhamomyces anomalus is an emerging fungal pathogen causing infections, particularly in neonates and ICU patients. This yeast shows minimal resistance to common antifungals, but mortality remains significant, necessitating further research.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Microbiology
Background:
- Wickerhamomyces anomalus, previously known as Hansenula anomala, Pichia anomala, or Candida pelliculosa, is increasingly recognized as an emerging human pathogen.
- Human infections caused by W. anomalus have been reported with rising frequency, highlighting its clinical significance.
Purpose of the Study:
- To review and synthesize data on the epidemiology, antifungal resistance, clinical characteristics, treatment, and outcomes of fungemia caused by Wickerhamomyces anomalus.
- To consolidate information from published reports to better understand this emerging infectious agent.
Main Methods:
- A systematic literature search was conducted using PubMed/Medline, Cochrane Library, and Scopus databases.
- Data from 36 studies involving 170 patients with W. anomalus fungemia were extracted and analyzed.
Main Results:
- The study included 170 patients, with a mean age of 22.8 years; over 37 were neonates, and 54% were male.
- Common risk factors included central venous catheter use (70.4%), total parenteral nutrition (28.7%), and intensive care unit (ICU) hospitalization (39.4%).
- W. anomalus demonstrated minimal antifungal resistance to fluconazole, echinocandins, and amphotericin B. Fever (95.8%) and sepsis (86%) were the most common presentations. Overall mortality was 20%.
Conclusions:
- Wickerhamomyces anomalus fungemia predominantly affects vulnerable populations, including neonates and ICU patients, often associated with invasive devices.
- The yeast exhibits low resistance to standard antifungal therapies, yet the overall mortality rate necessitates careful clinical management.
- Further multicenter studies are crucial to comprehensively characterize patient profiles, optimize treatment strategies, and improve outcomes for W. anomalus infections.
More Related Videos
Related Concept Videos
Overview of Fungi
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota

